The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ENTX | -20% | +62.62% | +10.21% | -72% |
| S&P | +14.77% | +87.2% | +13.35% | +155% |
Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. It s pipeline include PTH, GLP-E, and hGh, The company was founded on September 30, 2009 and is headquartered in Jerusalem, Israel.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | -100.0% |
| Gross Profit | -$8.00K | 0.0% |
| Gross Margin | 0.00% | 0.0% |
| Market Cap | $87.67M | 27.0% |
| Market Cap / Employee | $3.99M | 15.5% |
| Employees | 22 | 10.0% |
| Net Income | -$3,200.00K | -5.9% |
| EBITDA | -$3,248.00K | -7.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $16.60M | 137.4% |
| Accounts Receivable | $0.00K | -100.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $41.00K | -72.1% |
| Short Term Debt | $170.00K | 4.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -85.74% | 26.8% |
| Return On Invested Capital | -101.94% | -5.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2,786.56K | -29.0% |
| Operating Free Cash Flow | -$2,740.08K | -26.9% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 12.00 | 8.17 | 4.45 | 5.06 | -37.46% |
| Price to Sales | 454.89 | 330.68 | 536.08 | 729.13 | 0.92% |
| Price to Tangible Book Value | 12.00 | 8.17 | 4.45 | 5.06 | -37.46% |
| Enterprise Value to EBITDA | -31.79 | -20.90 | -26.43 | -22.79 | 5.79% |
| Return on Equity | -103.3% | -71.5% | -82.2% | -99.4% | -31.27% |
| Total Debt | $272.00K | $220.00K | $203.00K | $211.00K | -31.72% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
